Trial Profile
Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.
- 30 Jan 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.